ControversyEpirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity
References (123)
- et al.
Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety
Chem.-Biol. Interactions
(1977) - et al.
Experimental systemic toxicology of 4′epidoxorubicin, a new less cardiotoxic anthracycline antitumour agent
Toxicol. Appl. Pharmacol.
(1985) - et al.
Absorption of epi-doxorubicin after intravesical administration in patients with in situ transitional cell carcinoma of the bladder
Eur. J. Cancer Clin. Oncol.
(1987) - et al.
Studies on the intravesical action of topically administered G3H-doxorubicin hydrochloride in men: plasma uptake and tumour penetration
J. Urol.
(1980) - et al.
Metabolism of 4′-modified analogs of doxorubicin
- et al.
Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry: initial weekly treatment followed by rescheduling and intensification
Ann. Oncol.
(1991) How much drug in the tablet?
Lancet
(1991)Effective palliation of advanced breast cancer with weekly low dose epirubicin
Eur. J. Cancer Clin. Oncol.
(1989)- et al.
Weekly low dosage epirubicin in advanced breast cancer
Eur. J. Cancer
(1990) - et al.
Weekly adriamycin vs 4-epidoxorubicin every second week in advanced breast cancer
Adriamycin versus epirubicin in advanced soft tissue sarcomas
High-dose epirubicin chemotherapy in untreated poorer prognosis small-cell lung cancer
Respir. Med.
Combination chemotherapy with vincristine, epirubicin and cyclophosphamide in small-cell lung carcinoma
Eur. J. Cancer
Activity of high-dose epirubicin in advanced non-small-cell lung cancer
Eur. J. Cancer
Adriamycin, 14-Hydroxydaunomycin, a new antitumour antibiotic from S peucetius var. caesius
Biotechnol. Bioeng.
Structure and physicochemical properties of Adriamycin (Doxorubicin)
Clinical evaluation of Adriamycin, a new antitumour antibiotic
BMJ
Adriamycin, the therapeutic activity on experimental tumours
Adriamycin, a new anticancer drug with significant clinical activity
Ann. Intern. Med.
Adriamycin, a review
J. Natl. Cancer Inst.
Adriamycin, an antitumour antibiotic: a review with special reference to daunomycin
Dan. Med. Bull.
La Daunomicina: Un nuovo antiobiotico ad attivita citostatica, isolamento e proprieta
Gior. Microbiol.
Present role of doxorubicin (Adriamycin) in the treatment of neoplastic disease
Clin. Trials J.
Chemistry and pharmacology of new antitumour anthracyclines
New antitumour anthracyclines
Lloydia
Antitumour anthracyclines: new developments
Process Biochem.
Synthesis and antitumour properties of new glycosides of daunomycinone and adriamycinone
J. Med. Chem.
Antitumour activity, toxicity and pharmacological properties of 4′epiadriamycin
Properties of antitumour anthracyclines and new developments in their application: Cain memorial award lecture
Cancer Res.
Chelation of copper(II) ions by doxorubicin and 4′-epidoxorubicin: an e.s.r. study
Anti-Cancer Drug Design
Chemistry of epirubicin
Cellular Pharmcodynamics of several anthracycline antibiotics
J. Med. Chem.
In vitro chemosensitivity testing using the multicellular tumour spheroid model
Cancer Drug Delivery
Aspects of cytotoxic drug penetration; thesis for submission for the degree of MD, Department of Medical Biology, University of Glasgow
Intravesical chemotherapy: Studies on the relationship between pH and cytotoxicity
Cancer
Comparative effects of doxorubicin and 4′-epi-doxorubicin on nucleic acid metabolism and cytotoxicity in a human tumour cell line
Cancer Chemother. Pharmacol.
Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and Lovo/Dx human cell lines
Anti-cancer Drug Design
Comparison of the intracellular pharmacokinetics of doxorubicin and 4′-epi-doxorubicin in patients with acute leukemia
Cancer Chemother. Pharmacol.
Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal haematopoietic cells
Cancer Chemother. Pharmacol.
The use of 4′-epirubicin intravesically for the treatment of difficult-to-control superficial bladder cancer
Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer
Cancer Treat. Rep.
Biliary excretion and pharmacokinetics of 4′-epidoxorubicin (epirubicin) in advanced cancer patients
Cancer Chemother. Pharmacol.
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans
J. Clin. Oncol.
Epirubicin and doxorubicin comparative metabolism and pharmacokinetics; a cross-over study
Cancer Chemother. Pharmacol.
Pharmacokinetics and metabolism of adriamycin in man
Clin. Pharmacol. Ther.
Adriamycin chemotherapy-efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule
Cancer
Is glucuronidation truly preserved in patients with liver disease?
Hepatology
Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry
Br. J. Cancer
Pharmacokinetics of epirubicin (EPI) in patients with abnormal liver biochemistry
Br. J. Cancer
Comparative pharmacokinetics and metabolism of doxorubicin (DOX) and epidoxorubicin (EPI) in relation to liver biochemistry tests
Br. J. Cancer
Cited by (187)
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
2023, Molecular Aspects of MedicineA druggable pocket on PSMD10<sup>Gankyrin</sup> that can accommodate an interface peptide and doxorubicin
2022, European Journal of PharmacologyCitation Excerpt :Doxorubicin and epirubicin both have moderate binding affinities for PSMD10Gankyrin, indicating that the interaction occurs mainly through the anthracycline ring and the hydroxyl group of C4’ has very little/no role in the interaction (Fig. 4) at least as seen from equilibrium studies. Doxorubicin and epirubicin, are potent anti-cancer drugs used in the treatment of cancers, especially breast cancer (Khasraw et al., 2012; Paul Launchbury and Habboubi, 1993). The main target for these drugs is DNA topoisomerase II and the drugs bind to DNA topoisomerase II or intercalate to DNA.
Ofloxacin@Doxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections
2022, Bioorganic ChemistryCitation Excerpt :Regarding both epirubicin [40] and doxorubicin [41], these drugs are also positively charged at physiological pH, resulting in attractive electrostatic interactions. The pKa values of 8.22 and 8.34 for doxorubicin, and 7.7 and 8.08 for epirubicin, indicate that these molecules exist mainly in a cationic form within a pH range from about 5 to 9 [42]. This suggests that these drugs will have a more positive charge than ofloxacin, resulting in higher loading percentages.
Synthetic (N, N-Dimethyl)doxorubicin Glycosyl Diastereomers to Dissect Modes of Action of Anthracycline Anticancer Drugs
2021, Journal of Organic Chemistry